Table 3.
Characteristics of the MA/RIC transplant cohort (n=821), by antibiotic prophylaxis
| Characteristic | None N (%) | Vancomycin Only N (%) | Vancomycin+FQ N (%) | FQ Only N (%) |
|---|---|---|---|---|
| Total N=140 | Total N=405 | Total N=240 | Total N=36 | |
| Age | ||||
| Median age, years (Range) | 47.2 (21.6 - 71.1) | 49 .8 (18.5 - 73) | 52.9 (21.4 - 71.3) | 46 .8 (21.6 - 68.4) |
| Sex | ||||
| Male | 67 (48) | 246 (61) | 128 (53) | 22 (61) |
| Female | 73 (52) | 159 (39) | 112 (47) | 14 (39) |
| Diagnosis | ||||
| Acute Leukemia/MDS | 89 (63) | 290 (72) | 189 (79) | 25 (69) |
| CML | 19 (14) | 19 (5) | 6 (3) | 1 (3) |
| Lymphoma/CLL | 24 (17) | 66 (16) | 30 (12) | 8 (22) |
| Multiple myeloma | 5 (4) | 26 (6) | 12 (5) | 1 (3) |
| Other1 | 3 (2) | 2 (1) | 3 (1) | 1 (3) |
| Donor Type | ||||
| Matched related | 89 (63) | 158 (39) | 75 (31) | 5 (14) |
| Matched unrelated | 32 (23) | 138 (34) | 71 (30) | 15 (42) |
| Mismatched2 | 19 (14) | 109 (27) | 94 (39) | 16 (44) |
| Stem Cell Source | ||||
| Bone marrow | 55 (39) | 34 (8) | 16 (7) | 5 (14) |
| Peripheral blood | 85 (61) | 342 (85) | 188 (78) | 22 (61) |
| Umbilical cord blood | 0 (0) | 29 (7) | 36 (15) | 9 (25) |
| T-Cell Depletion | ||||
| No | 56 (40) | 139 (34) | 81 (34) | 21 (58) |
| Yes | 84 (60) | 266 (66) | 159 (66) | 15 (42) |
| Conditioning | ||||
| Myeloablative | 112 (80) | 272 (67) | 140 (58) | 19 (53) |
| Reduced intensity | 28 (20) | 133 (33) | 100 (42) | 17 (47) |
| Transplant Period | ||||
| Early Period (2000-2005) | 131 (94) | 101 (25) | 43 (18) | 11 (31) |
| Recent Period (2006-2011) | 9 (6) | 304 (75) | 197 (82) | 25 (69) |
Continuous variables are displayed as mean (range), categorical variables are displayed as N (%).
1
Other: Myeloproliferative disorder, solid tumor, non-malignant hematologic disorder.
2
related or unrelated.
Abbreviations: MDS: myelodysplastic syndrome; CML: chronic myeloid leukemia; CLL: chronic lymphocytic leukemia.